scholarly journals Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect

2019 ◽  
Vol Volume 12 ◽  
pp. 223-228 ◽  
Author(s):  
Bagus Komang Satriyasa
Keyword(s):  
Botulinum Toxin ◽  
Literature Review ◽  
Clinical Use ◽  
Pharmacological Aspect

scholarly journals FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia

Toxins ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 332 ◽  
Author(s):  
Lauren L. Spiegel ◽  
Jill L. Ostrem ◽  
Ian O. Bledsoe
Keyword(s):  
Botulinum Toxin ◽  
Literature Review ◽  
American Academy ◽  
Practice Guidelines ◽  
European Federation ◽  
Botulinum Toxins ◽  
Consensus Guidelines ◽  
Off Label ◽  
Fda Approval ◽  
American Academy Of Neurology

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.

scholarly journals Botulinum Toxin: An Update on Pharmacology and Newer Products in Development

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 58
Author(s):  
Supriyo Choudhury ◽  
Mark R. Baker ◽  
Suparna Chatterjee ◽  
Hrishikesh Kumar
Keyword(s):  
Botulinum Toxin ◽  
Clinical Use ◽  
First Line ◽  
High Demand ◽  
Short Term ◽  
Medical Specialties ◽  
Naturally Occurring ◽  
Pharmacokinetic Properties ◽  
Clinical Benefits ◽  
First Line Treatment

Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects. To cater for the high demand across various medical specialties, at least six US Food and Drug Administration (FDA)-approved formulations of BoNT are currently available for diverse labelled indications. The toxo-pharmacological properties of these formulations are not uniform and thus should not be used interchangeably. Synthetic BoNTs and BoNTs from non-clostridial sources are not far from clinical use. Moreover, the study of mutations in naturally occurring toxins has led to modulation in the toxo-pharmacokinetic properties of BoNTs, including the duration and potency. We present an overview of the toxo-pharmacology of conventional and novel BoNT preparations, including those awaiting imminent translation from the laboratory to the clinic.

Stability of Botulinum Toxin in Clinical Use

1993 ◽  
pp. 661-663
Author(s):  
Henry T. Hoffman ◽  
Michael G. Gartlan
Keyword(s):  
Botulinum Toxin ◽  
Clinical Use

Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review

2018 ◽  
Vol 16 (4) ◽  
pp. 479-488 ◽  
Author(s):  
Ashley Thomas ◽  
Bruno de Souza Ribeiro ◽  
Miguel Malespin ◽  
Silvio W. de Melo
Keyword(s):  
Botulinum Toxin ◽  
Literature Review

scholarly journals Urodynamic studies and features of anaesthesia during intradetrusor botulinum therapy in the context of the COVID-19 pandemic (literature review)

2021 ◽  
Vol 65 (5) ◽  
pp. 485-491
Author(s):  
Dmitriy A. Lysachev ◽  
Lyubov A. Khodyreva ◽  
Roman V. Stroganov ◽  
Yuri A. Kupriyanov
Keyword(s):  
Botulinum Toxin ◽  
Urinary Tract ◽  
Literature Review ◽  
Local Anaesthesia ◽  
Botulinum Toxin Type A ◽  
Diagnostic Procedures ◽  
Botulinum Toxin Type ◽  
Upper Urinary Tract ◽  
Lower Urinary Tract Dysfunction ◽  
Urodynamic Studies

The coronavirus pandemic has had a severe impact on the health care system. It is also changing the appointment and conduct of diagnostic procedures, emergency and routine medical care. According to the medical guidelines of the European Society of Urology (EAU) for the provision of urological care during the current epidemic situation, various levels of urgency have been proposed for diagnostic and therapeutic measures depending on the type of disease. Urodynamic studies refer to studies with a priority level from P2 (for neurogenic dysfunction of the urinary tract) to P4 (for lower urinary tract dysfunction without the risk of damage to the upper urinary tract). The question arises regarding the safety of these studies, both for patients and medical staff, and possible measures to reduce the risk of infection in a viral pandemic. Because of the increased workload of hospitals that have not been redesigned for the fight against coronavirus infection and provide routine and emergency urological care, an even greater need has arisen to find effective and safe methods of local anaesthesia for performing urodynamic studies and intradetrusive injections of botulinum toxin type A under local anesthesia in outpatient and outpatient settings (for example, in a short-term hospital). This article presents a literature review on the principles and features of performing urodynamic studies in the context of the Covid-19 pandemic and the effectiveness and safety of using various methods of local anaesthesia when performing intradetrusor injections of botulinum toxin with detrusor hyperactivity of a neurogenic and non-neurogenic nature. There were evaluated forms of local anaesthesia such as intradetrusor instillation of lidocaine, electrophoresis, and the use of alternative solutions for urinary bladder irrigation (for example, Ringer’s solution).

Botulinum toxin type A as a novel method of preventing cleft lip scar hypertrophy—A literature review

2020 ◽  
Vol 19 (9) ◽  
pp. 2188-2193
Author(s):  
Patrycja Bartkowska ◽  
Justyna Roszak ◽  
Hubert Ostrowski ◽  
Oskar Komisarek
Keyword(s):  
Botulinum Toxin ◽  
Literature Review ◽  
Cleft Lip ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Novel Method ◽  
Scar Hypertrophy
Sign in / Sign up

Export Citation Format

Share Document